BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Custodio A, Puente J, Sastre J, Díaz-Rubio E. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev. 2009;35:676-684. [PMID: 19758760 DOI: 10.1016/j.ctrv.2009.08.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol 2016;33:37. [PMID: 26995224 DOI: 10.1007/s12032-016-0753-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 2014;14:398-402. [PMID: 25278310 DOI: 10.1016/j.pan.2014.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
3 Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer. Mol Pharmacol 2011;80:598-609. [DOI: 10.1124/mol.111.073627] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 11.2] [Reference Citation Analysis]
4 Power DG, Shia J, Allen PJ, Jarnagin WR, O'Reilly EM. Synchronous epithelial and neuroendocrine cancers of the pancreas: case series of a rare occurrence. Clin Colorectal Cancer 2011;10:146-50. [PMID: 21859569 DOI: 10.1016/j.clcc.2011.03.013] [Reference Citation Analysis]
5 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
6 Li YJ, Huang GL, Sun XL, Zhao XC, Li ZG. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J Surg Oncol 2016;14:60. [PMID: 26927794 DOI: 10.1186/s12957-016-0809-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, Valmadre G, Ferrara D, Veltri E, Codignola C, Labianca R. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012;69:1641-1645. [PMID: 22576338 DOI: 10.1007/s00280-012-1875-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
8 Tamarov KP, Osminkina LA, Zinovyev SV, Maximova KA, Kargina JV, Gongalsky MB, Ryabchikov Y, Al-Kattan A, Sviridov AP, Sentis M, Ivanov AV, Nikiforov VN, Kabashin AV, Timoshenko VY. Radio frequency radiation-induced hyperthermia using Si nanoparticle-based sensitizers for mild cancer therapy. Sci Rep 2014;4:7034. [PMID: 25391603 DOI: 10.1038/srep07034] [Cited by in Crossref: 100] [Cited by in F6Publishing: 84] [Article Influence: 12.5] [Reference Citation Analysis]
9 Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015;96:483-497. [PMID: 26481952 DOI: 10.1016/j.critrevonc.2015.07.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
10 Huang XY, Wang HC, Yuan Z, Li A, He ML, Ai KX, Zheng Q, Qin HL. Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin 2010;31:741-5. [PMID: 20523344 DOI: 10.1038/aps.2010.54] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
11 Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S, Sarkar FH. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer 2011;128:1240-50. [PMID: 20824697 DOI: 10.1002/ijc.25658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, Chen L, Liu L. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. International Journal of Hyperthermia 2011;27:101-7. [DOI: 10.3109/02656736.2010.525588] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
13 Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Clin Oncol (R Coll Radiol) 2012;24:105-11. [PMID: 21382702 DOI: 10.1016/j.clon.2011.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khan K, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife LR, Banerji U, de Bono JS, Cunningham D, Kaye SB. Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer 2014;17:621-9. [PMID: 24445485 DOI: 10.1007/s10120-013-0328-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Maginn EN, de Sousa CH, Wasan HS, Stronach EA. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Biochim Biophys Acta 2014;1846:45-54. [PMID: 24727386 DOI: 10.1016/j.bbcan.2014.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
16 Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53. [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
17 Glazer ES, Massey KL, Zhu C, Curley SA. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery 2010;148:319-24. [PMID: 20541785 DOI: 10.1016/j.surg.2010.04.025] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
18 Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treat Rev. 2016;50:142-147. [PMID: 27676174 DOI: 10.1016/j.ctrv.2016.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
19 Lee JE, Lee HS, Chung MJ, Park JY, Park SW, Song SY, Bang S. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Gut Liver 2020;14:135-43. [PMID: 30974927 DOI: 10.5009/gnl18419] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 2016;113:413-419. [PMID: 27100026 DOI: 10.1002/jso.24147] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Amini SM, Kharrazi S, Rezayat SM, Gilani K. Radiofrequency electric field hyperthermia with gold nanostructures: role of particle shape and surface chemistry. Artif Cells Nanomed Biotechnol 2018;46:1452-62. [PMID: 28891351 DOI: 10.1080/21691401.2017.1373656] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]